Hemodialysis using gabexate mesilate (FOY) in patients with a high bleeding risk
作者:
NOBUYUKI TAENAKA,
NAOHIRO TERADA,
HIDEO TAKAHASHI,
YUTAKA TACHIMORI,
TOSHIKI OKADA,
JUN TAKEZAWA,
YASUHIRO SHIMADA,
IKUTO YOSHIYA,
期刊:
Critical Care Medicine
(OVID Available online 1986)
卷期:
Volume 14,
issue 5
页码: 481-483
ISSN:0090-3493
年代: 1986
出版商: OVID
数据来源: OVID
摘要:
The efficacy of gabexate mesilate (FOY), a synthetic serine proteinase inhibitor, was compared with that of heparin in preventing the acceleration of bleeding after hemodialysis. Transfused blood volume (TBV) was measured 24 h before and after 24 dialyses in 14 bleeding patients with impaired hemostatic function. The predialysis TBV did not differ significantly between heparin and FOY groups; however, TBV was significantly (p< .05) larger after heparin dialysis than after FOY dialysis. After dialysis, TBV was increased in eight of nine heparin patients, compared to only three of 15 FOY subjects (p< .01). FOY is an effective agent and may decrease postdialysis bleeding complications in certain high-risk patients.
点击下载:
PDF
(199KB)
返 回